+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2029

  • ID: 5147742
  • Report
  • September 2020
  • Region: Global
  • 37 pages
  • GlobalData
Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2029

Summary

Amyotrophic lateral sclerosis (ALS) is a group of rare but fatal neurodegenerative diseases that primarily involve the nerve cells (neurons) in the brain and spinal cord responsible for controlling voluntary muscle movement like chewing, walking, and talking (National Institute of Neurological Disorders and Stroke, 2020). ALS is often called Lou Gehrig's disease, after the baseball player who was diagnosed with the disease in 1939 (Mayo Clinic, 2019). Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear. Currently, there is no cure for ALS and no effective treatment to stop, or reverse, the progression of the disease (National Institute of Neurological Disorders and Stroke, 2020).

The publisher epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast. The disease definition for ALS was based on El Escorial criteria or the ICD-9 criteria (ICD-9 code: 335.2). The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of ALS in the 8MM, segmented by age, sex, and type.

The following data describes epidemiology of ALS. In the 8MM, the publisher's epidemiologists forecast an increase in the total prevalent cases of ALS from 74,614 cases in 2019 to 80,483 cases in 2029 at an AGR of 0.79% during the forecast period. In the 8MM, the diagnosed prevalent cases of ALS will increase from 57,750 cases in 2019 to 65,886 cases in 2029 at an AGR of 1.41% during the forecast period. ALS is predominant in the older age group globally and its prevalence increases with advancing age until the 70s or 80s. These trends are reflected in the publisher’s forecast for the total prevalent cases, and diagnosed prevalent cases for the 8MM.

Scope
  • The Amyotrophic Lateral Sclerosis (ALS) Epidemiology Report provides an overview of the risk factors and global trends of ALS in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
  • The report includes a 10-year epidemiological forecast for the prevalent cases of ALS (total and diagnosed) segmented by sex, age (ages ≥40 years), and type (familial and sporadic) in these markets. In addition, the model corresponding to this report includes incident cases of ALS for ages 40 years and older.
  • The ALS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy

The Amyotrophic Lateral Sclerosis Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global ALS market.
  • Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ALS therapeutics in each of the markets covered.
  • Understand magnitude of ALS population by severity at diagnosis.
Note: Product cover images may vary from those shown
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Amyotrophic Lateral Sclerosis: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for ALS (2019-2029)
3.5.1 Total Prevalent Cases of ALS
3.5.2 Sex-Specific Total Prevalent Cases of ALS
3.5.3 Age-Specific Total Prevalent Cases of ALS
3.5.4 Total Prevalent Cases of ALS by Type
3.5.5 Diagnosed Prevalent Cases of ALS
3.5.6 Sex-Specific Diagnosed Prevalent Cases of ALS
3.5.7 Age-Specific Diagnosed Prevalent Cases of ALS
3.5.8 Diagnosed Prevalent Cases of ALS by Type
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for this Report
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About the Publisher
4.5 Contact
4.6 Disclaimer

List of Tables
Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for ALS

List of Figures
Figure 1: 8MM, Total Prevalent Cases of ALS, Both Sexes, Ages ≥40 Years, 2019 and 2029
Figure 2: 8MM, Diagnosed Prevalent Cases of ALS, Both Sexes, Ages ≥40 Years, 2019 and 2029
Figure 3: 8MM, Total Prevalence of ALS (%), Both Sexes, Ages ≥40 Years, 2019
Figure 4: 8MM, Diagnosed Prevalence of ALS, Both Sexes, Ages ≥40 Years, 2019
Figure 5: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of ALS
Figure 6: 8MM, Sources Used to Forecast the Total and Diagnosed Prevalent Cases of ALS by Type
Figure 7: 8MM, Total Prevalent Cases of ALS, N, Both Sexes, Ages ≥40 Years, 2019
Figure 8: 8MM, Total Prevalent Cases of ALS, N, by Sex, Ages ≥40 Years, 2019
Figure 9: 8MM, Total Prevalent Cases of ALS by Age, N, Both Sexes, 2019
Figure 10: 8MM, Total Prevalent Cases of ALS by Type, N, Both Sexes, Ages ≥40 Years, 2019
Figure 11: 8MM, Diagnosed Prevalent Cases of ALS, N, Both Sexes, Ages ≥40 Years, 2019
Figure 12: 8MM, Diagnosed Prevalent Cases of ALS, N, by Sex, Ages ≥40 Years, 2019
Figure 13: 8MM, Diagnosed Prevalent Cases of ALS by Age, N, Both Sexes, 2019
Figure 14: 8MM, Diagnosed Prevalent Cases of ALS by Type, N, Both Sexes, Ages ≥40 Years, 2019
Note: Product cover images may vary from those shown
Adroll
adroll